IDH1 expression via the R132H mutation–specific antibody in adrenocortical neoplasias - prognostic impact in carcinomas

Mirkka Pennanen¹, Olli Tynninen¹, Soili Kytölä², Pekka Ellonen³, Harri Mustonen⁴, Ilkka Heiskanen⁴, Caj Haglund⁴,⁵*, and Johanna Arola¹*

¹Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

²Department of Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

³Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland

⁴Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

⁵Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland

*shared last authorship
Corresponding author: Mirkka Pennanen, Department of Pathology, Haartman Institute,
PO Box 21, 00014 University of Helsinki, Finland
Email: mirkka.pennanen@helsinki.fi

Funding: Finnish Cancer Foundation (MP, CH, and JA), Liv & Hälsa Foundation, Helsinki University Hospital Research Fund (CH and JA), Sigrid Jusélius Foundation (CH), Biocenter Finland (PE)

Disclosure statement: The authors have nothing to disclose.
ABSTRACT

Context: Mutations to isocitrate dehydrogenase (IDH) appear to play a prognostic or predictive role in several neoplasias. Immunohistochemical staining designed to detect a specific R132H mutation to IDH1 showed expression in the normal adrenal cortex, raising interest to study the potential role of IDH1 in the pathogenesis of adrenocortical tumors.

Objective: To study the role of IDH1 and its mutations in adrenocortical tumors.

Design and Patients: IDH1 R132H immunohistological staining was performed on a cohort of 197 adrenocortical tumors. The exon of the IDH1 gene was sequenced in 16 tumors.

Results: Positive IDH1 R132H immunohistochemical staining correlated with a better prognosis among patients with a malignant adrenocortical tumor. However, IDH1 R132H immunohistochemistry did not distinguish between local and metastasized tumors. We were unable to identify IDH1 mutations among our adrenocortical tumors using a targeted NGS panel or via exon sequencing.

Conclusions: Among adrenocortical carcinomas, IDH1 R132H immunopositivity correlated with a better prognosis. Thus, IDH1 R132H immunohistochemical staining could serve as a prognostic or as a potential predictive marker in adrenocortical carcinomas. Further research is needed to identify the possible alterations in IDH1 that could explain our findings, since we identified no known mutations to the IDH1 gene.
Keywords: adrenocortical tumor, IDH1

PRÉCIS

IDH1 R132H mutation-specific antibody stains adrenocortical tumors, but no known IDH1 gene mutations were found. Yet, positive staining predicts longer survival in metastasized carcinomas.
INTRODUCTION

Adrenocortical tumors have emerged as an important clinical issue given the widespread use of high-resolution imaging and the increased prevalence of these lesions. Most adrenocortical tumors are benign adenomas which can be cured through the unilateral removal of the adrenal gland. Rare adrenocortical carcinomas are accompanied by a poor prognosis, and postoperative treatment options for them remain scarce. Understanding the pathogenesis of adrenocortical tumors would lead to the more accurate diagnosis of these tumors and may offer targets for the treatment of malignant tumors.

Isocitrate dehydrogenase (IDH) is a metabolic enzyme, ubiquitous in all cells of the body, responsible for the oxidation of isocitrate to α-ketoglutarate and the conversion of NAD(P)\(^+\) to NAD(P)H. IDH exists in three isoforms. Mutations of IDH isoforms 1 and 2 were first identified in gliomas (1), and have since been reported in several neoplasias (2–5). The mutated form of IDH gains neomorphic activity, resulting in the conversion of α-ketoglutarate to an oncometabolite, D-2-hydroxyglutarate. The subsequent accumulation of the oncometabolite results in epigenetic dysregulation by inhibition of the α-ketoglutarate-dependent histone and DNA demethylases, and a block in cellular differentiation (6, 7).

In gliomas, the status of an IDH mutation is an important diagnostic and prognostic feature, determined during routine clinical practice. IDH mutations occur in most lower-grade gliomas and secondary glioblastomas, indicative of a distinctive pathogenesis and a better prognosis compared to primary
glioblastomas. A specific R132H mutation to IDH1 accompanies approximately 80% of all IDH mutations in gliomas (8), and can be depicted from formalin-fixed paraffin-embedded tissues through immunohistochemistry using an antibody against the mutated protein (9). In adrenocortical tumors, IDH1 and 2 mutations have thus far remained unreported. Interestingly, another research group in Helsinki found an immunohistochemical positivity for IDH1 R132H in the normal adrenal cortex (oral communication). This finding piqued our interest in examining the IDH1 R132H expression in adrenocortical tumors.

Thus, we aimed to study the role of IDH1 and its possible mutations in a large cohort of clinically verified adrenocortical tumors.

MATERIALS AND METHODS

Clinical data and tumor material

We identified all adult patients who underwent surgery for a primary adrenocortical tumor at the Department of Surgery, Helsinki University Hospital (HUH) between 1990 and 2003. The series comprised 195 patients with 197 tumors (two patients had two separate tumors). The tumor specimens were taken from the archives of the Department of Pathology, and clinical data were collected from patient records. We gathered survival data and cause of death information from the Population Register Center and Statistics Finland.
The Ethics Committee of Helsinki University Hospital and the National Supervisory Authority for Welfare and Health approved the study protocol.

The clinical characteristics of tumor patients are shown in Table 1. Among the 195 tumor patients, 14 died from adrenocortical carcinoma. These patients had metastatic disease and their survival time ranged from 0.30 to 6.84 years (median, 2.05; mean, 2.97) after primary surgery. During follow-up, 36 patients died of causes other than an adrenocortical tumor. Among patients alive at the end of the study, the follow-up time ranged from 7.84 to 21.83 years (median, 11.27; mean, 12.64).

Material for genetic analysis

To identify mutations of IDH1 at Arg132 using amplicon-based hot spot panel sequencing, we chose 10 tumors with Weiss scores of 3 to 9, 5 of which exhibited strong positive and 5 exhibited negative IDH1 R132H immunohistochemical staining (Figure 1).

For IDH1 gene sequencing from the formalin-fixed paraffin-embedded tumor material, we chose an additional 10 tumors, 5 tumors with Weiss scores of 0 to 2 with positive IDH1 R132H immunohistochemistry and 5 tumors with Weiss scores of 3 to 9 with low positivity. In total, we analyzed 20 tumors.
Among these 20 tumors, we had fresh frozen tumor material available for IDH1 gene sequencing for 16 tumors.

**Histopathology**

The histopathological diagnosis using the Weiss score (10, 11) for each tumor was reviewed by two endocrine pathologists (MP and JA) based on hematoxylin- and eosin- (HE) stained sections. The novel Helsinki score, introduced by the authors (12), was also determined. The Helsinki score consists of $3 \times$ mitotic rate ($>5/50$ hpf) + $5 \times$ presence of necrosis + proliferation index (Ki67/mib index). A score $>8.5$ indicates metastatic carcinoma with a sensitivity of 100%.

**Tissue microarray (TMA) construction**

Tissue microarray (TMA) blocks were constructed from archived surgical formalin-fixed paraffin-embedded specimens. Representative areas of each tumor were chosen from HE-stained slides. Using a semiautomatic TMA instrument (Beecher Instruments, Silver Spring, MD, USA), three 1-mm cores were obtained from each histologically benign (Weiss score 0–2) tumor, and six cores were taken from the histologically malignant (Weiss score 3–9) tumors. In addition, two cores from the normal adrenal cortex were taken from each specimen.
Immunohistochemistry

TMA blocks were cut into 4-µm sections. For antigen retrieval, slides were treated in a PreTreatment module (Lab Vision Corporation, Fremont, CA) in a Tris-EDTA (pH 9.0) buffer for 20 min at 98°C. Immunohistochemical staining was performed using the EnVision™ polymer detection kit (Dako, Glostrup, Denmark) in a LabVision Autostainer (Thermo Scientific, Fremont CA). Sections were incubated with the mouse monoclonal IDH1 R132H antibody (clone H09, Dianova, Hamburg, Germany) (13) at a dilution of 1:20 for 30 min at room temperature. The slides were counterstained with Mayer’s Hematoxylin (Lillie’s Modification; Dako) and mounted using Mountex™ (Histolab, Järfälla, Sweden).

Interpretation of immunohistochemical staining

IDH1 R132H immunohistochemical expression was determined in 195 tumors. Staining was scored independently by two experienced pathologists (MP and OT). Any discrepancies between scores were resolved through consensus.

The intensity of the cytoplasmic staining of IDH1 R132H, that is the amount of positively staining granules, was scored on a scale from 0 to 3. The staining was fairly evenly distributed throughout the tumor tissue. Therefore, the extension of the staining was not scored. Negative cytoplasmic staining was scored as 0, weakly positive as 1, moderately strongly positive or a focally
strong positivity as 2, and a strong positivity as 3. For all of the stained samples for each tumor, the highest score was used for further analysis.

**Amplicon-based hot spot panel sequencing**

DNA was extracted from 10 FFPE samples following deparaffinization using the Maxwell® LEV Blood DNA Kit (Promega Corporation, Madison WI) according to the manufacturer’s instructions. The tumor content of each sample was evaluated from HE-stained slides by an experienced pathologist (MP).

DNA was subjected to library preparation using the Ion AmpliSeq Cancer Hot Spot Panel version 2, designed to target 2800 COSMIC mutations from 50 oncogenes and tumor suppressor genes, and sequenced on the Ion Torrent PGM™ System (Thermo Fisher Scientific, Waltham; MA). The panel covers 15 and 11 hot spot regions in IDH1 including the R132 and IDH2 genes, respectively. Library preparation, template preparation, and the sequencing were carried out according to the manufacturer’s instructions (Life Technologies, Carlsbad, CA, USA). Data analysis was performed using the Torrent Suite Software version 4.0. After trimming and alignment to the hg19 human reference genome, sequence variants were detected using the VariantCaller version 4.0. The Ion Reporter software version 4.0 was used to filter out noncoding and polymorphic variants.
Hybridization capture–based targeted sequencing

For preparing paired-end libraries, 7000 to 32 000 ng of DNA extracted from FFPE blocks (n=20) were used. For fresh frozen samples (n=16), 2300 to 14 300 ng of DNA was used as the input (ThruPlex DNA-Seq Kit, Rubicon Genomics, Ann Arbor, MI). Target enrichment was performed using the SeqCap EZ Comprehensive Cancer panel (Roche NimbleGen, Madison, WI). The panel covers 9 exons and the 5’ UTR region of the IDH1 gene, including the mutation sites of the Hot Spot Panel version 2. The enriched libraries were sequenced using the HiSeq2000 instrument with a paired-end 100-bp read length. Sequence analysis and variant calling were performed by an in-house bioinformatics pipeline [VCP, Variant Calling PipelineVCP (14)]. In addition to variant calling algorithms, IDH1 mutation hot spot loci were also visually inspected from the .bam files using IGV [Integrative Genome Viewer (15)]. The library preparation, sequencing, variant calling, and data analysis for this experiment were performed by the FIMM Sequencing Unit, HiLIFE, at the University of Helsinki.

Statistical analysis

Results are stated as the median, range, or the number of patients. Comparison between groups was performed using the Mann–Whitney test and the Fisher’s exact test for continuous and dichotomous variables, respectively. Correlations were tested by calculating the Spearman’s rho correlation coefficient. The Kaplan–Meier method with the log-rank test was used to compare survival between groups. We consisted a p-value <0.05 as statistically significant and
relied on two-tailed tests. All analyses were performed using SPSS version 24 (IBM, New York, NY, USA).

RESULTS

IDH1 R132H immunohistochemical staining of the normal adrenal cortex and adrenocortical neoplasias

The IDH1 R132H immunohistochemical staining appeared as granular cytoplasmic positivity in adrenocortical tumors. A similar staining was seen in the normal adrenal cortex (Figure 2). The intensity of the staining, that is the amount of positive granules, varied. Figure 2 shows the pattern and differences in the IDH1 R132H stainings.

The IDH1 R132H staining appeared in both benign and malignant tumors, and negative vs. positive staining could not distinguish between local and metastatic disease (p=0.359). In the entire tumor material, the IDH1 R132H staining (negative vs. positive) and Weiss score (0–2 vs. 3–9) did not correlate (p=0.312) nor did the IDH1 R132H staining and Helsinki score (<8.5 vs. ≥8.5; p=0.212). In histologically malignant tumors (Weiss score 3–9), the IDH1 R132H staining (negative vs. positive) correlated with the Helsinki score (<8.5 vs. ≥8.5; R²=-0.437, p=0.012).
Aldosterone secretion of the tumor correlated with a weak IDH1 R132H staining ($R^2 = -0.163$, $p=0.023$), whereas cortisol secretion correlated with a strong IDH1 R132H staining ($R^2 = 0.243$, $p=0.001$). We found no correlation between the IDH1 R132H staining and testosterone secretion ($R^2 = 0.071$, $p=0.326$) or with hormonal inactivity ($R^2 = -0.132$, $p=0.066$).

**Prognostic significance of IDH1 R132H immunohistochemistry in adrenocortical carcinomas**

To examine the possible prognostic significance of the IDH1 R132H staining in adrenocortical carcinomas, we chose all 33 tumors with a Weiss score of 3 to 9, defined as malignant according to the World Health Organization’s classification. Patients with a positive IDH1 R132H staining survived longer than patients with a negative staining ($p=0.031$; Figure 3).

**Amplicon-based hot spot panel sequencing**

The data analysis of the hot spot mutations revealed no mutations in the IDH1 or IDH2 genes with a sensitivity of 2%.

**Hybridization capture–based targeted sequencing**

From the FFPE-derived samples, we received no informative sequencing data. Initial sequencing provided the mean target coverage of the sequencing depth after the removal of duplicates. Sequencing delivered depths of 115 to 505x;
yet, after PCR duplicate removal the informative depth diminished to 2 to 13x. Evidently, the samples contained sufficient DNA molecules (mass), but the mass was heavily cross-linked and/or fragmented, thereby preventing successful library preparation. Such DNA behaves seemingly well in PCR amplicons–based methods, but lacks true somatic resolution given the limited number of accessible DNA template molecules.

Using the same protocol for the DNA from fresh frozen samples, we yielded sequencing depths ranging from 100 to 500x after PCR duplicate removal, which enabled us to perform somatic mutation calling. We failed to identify any known hot spot mutation or any novel variants in the IDH1 gene or the untranslated (UTR) regions (16).

**DISCUSSION**

In a large cohort of adrenocortical tumors, we found that mutation specific IDH1 R132H immunopositivity correlated with a better prognosis among adrenocortical carcinoma patients, suggesting a distinct pathogenic pathway among these tumors. However, IDH1 R132H immunohistochemistry did not correlate with the prognostic scoring systems used for adrenocortical tumors, such as the Weiss score or the Helsinki score, nor did it distinguish between local and metastasized disease. However, through genetic analysis, we failed to identify any known or novel IDH1 mutations in our adrenocortical tumor cohort.
The IDH1 R132H antibody used for the immunohistochemical staining was developed to specifically recognize the R132H mutated form of the IDH1 protein, the most frequent mutation seen in secondary glioblastomas. All reported pathogenic mutations of IDH1 are heterozygous missense point mutations that alter the conserved binding site of the homodimer enzyme. These most often occur at codon 132 by replacing arginine with another amino acid. To improve the diagnostic procedure of gliomas, Capper et al. (9) developed the IDH1 R132H antibody that binds to IDH1, where histidine replaces arginine 132. This mutation-specific antibody does not detect other mutated forms of IDH1, such as R132S, R132C, R132G, or R132L, nor does it bind to or cross react with wild-type IDH1. We only found one study that reported any positivity in tumor cells using the IDH1 R132H antibody in tumors negative for the R132H mutation through DNA sequencing. Amary et al. (4) studied IDH1 and 2 mutations in cartilaginous tumors, finding five R132H immunopositive tumors in which the mutation remained undetected through sequencing. They assumed that the amount and proportion of tumor cell DNA in the sample was too low for sequencing, concluding that the IDH1 R132H immunohistochemical staining was, in fact, more sensitive in identifying the mutation than sequencing. Against this background, we were surprised to find IDH1 R132H staining in the normal adrenal cortex and in adrenocortical tumors. Furthermore, we observed a granular cytosolic staining similar to that in IDH1 R132H–mutated gliomas, although less intensive. To verify the specific R132H mutation of IDH1 in these tumors, we performed an NGS mutational analysis of codon 132, but failed to detect any of the
previously reported mutations. Therefore, we searched for other possible mutations and sequenced the IDH1 exon of 16 tumors. This method revealed no relevant IDH1 mutations. Thus, the discrepancy between the positive immunohistochemical expression in the adrenal cortex and in the adrenocortical tumors and the negative mutation remains unclear. We speculate that there may be a post-transcriptional modification of the RNA or a conformational alteration of the protein.

Since adrenocortical carcinomas carry a poor prognosis and postoperative treatment options thus far remain limited, new treatment targets are needed. Mutated IDH offers a distinct target for specific, individualized therapies. Small molecule inhibitors of mutated IDH and peptide vaccines are being investigated for treating IDH-mutated neoplasms (17, 18). Binding of the IDH1 R132H antibody to a proportion of adrenocortical tumors indicates that the new IDH targeted therapies could benefit this subset of tumor patients.

A major advantage to our study is the large cohort size and the comprehensive follow-up data available for all patients. The fact that IDH1 R132H immunohistochemical stainings revealed a significant difference in survival between immunopositive and immunonegative malignant tumors indicates that the antibody detects an epitope with clinical relevance. The survival difference could be associated with the natural disease progression or the treatment response of different tumor subtypes. One weakness of our study stems from
our inability to identify the epitope that the IDH1 R132H antibody binds to in adrenocortical tumors.

In conclusion, among adrenocortical carcinomas, IDH1 R132H immunopositivity correlated with a better prognosis. Thus, IDH1 R132H staining could serve as a prognostic or as a predictive marker in adrenocortical carcinomas, discerning a subset of tumors with a particular pathogenic pathway. Further research is needed to uncover the possible alterations in IDH1 that explain our findings, since we failed to find mutations to the IDH1 gene.
ACKNOWLEDGEMENTS

We thank Eija Heiliö and Päivi Peltomäki for their technical support.
REFERENCES

1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. *Science*. 2008;321(5897):1807-1812.

2. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, DiPersio JF, Wilson RK, Ley TJ. Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med*. 2009;361(11):1058-1066.

3. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in
cholangiocarcinoma identified through broad-based tumor genotyping.

*Oncologist*. 2012;**17**(1):72-79.

4. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PC, Futreal A, Tirabosco R, Flanagan AM. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. *J Pathol*. 2011;**224**(3):334-343.

5. Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. *Biochem Biophys Res Commun*. 2010;**393**(3):555-559.

6. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M, McDonough MA, King ON, Clifton IJ, Klose RJ, Claridge TD, Ratcliffe PJ, Schofield CJ, Kawamura A. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. *EMBO Rep*. 2011;**12**(5):463-469.

7. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, Travins J, Weiss S, Looper R, Ligon KL, Verhaak RG, Yan H, Kaelin WG. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. *Nature*. 2012;**483**(7390):484-488.
8. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reiftenberger G, von Deimling A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. *Acta Neuropathol.* 2009;118(4):469-474.

9. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. *Acta Neuropathol.* 2009;118(5):599-601.

10. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. *Am J Surg Pathol.* 1984;8(3):163-169.

11. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. *Am J Surg Pathol.* 1989;13(3):202-206.

12. Pennanen M, Heiskanen I, Sane T, Remes S, Mustonen H, Haglund C, Arola J. Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas. *Hum Pathol.* 2015;46(3):404-410.

13. RRID:AB_2335716, https://scicrunch.org/resolver/AB_2335716

14. Sulonen AM, Ellonen P, Almusa H, Lepisto M, Eldfors S, Hannula S, Miettinen T, Tyynismaa H, Salo P, Heckman C, Joensuu H, Raivio T, Suomalainen A, Saarela J. Comparison of solution-based exome capture methods for next generation sequencing. *Genome Biol.* 2011;12(9):R9-r94.
15. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. *Nat Biotechnol.* 2011;29(1):24-26.

16. Pennanen M. Data from: IDH1 exon sequencing. Sequence Read Archive 2020. Accession number: PRJNA603119. https://www.ncbi.nlm.nih.gov/sra/PRJNA603119

17. Friedrich M, Bunse L, Wick W, Platten M. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. *Curr Opin Oncol.* 2018;30(6):368-374.

18. Golub D, Iyengar N, Dogra S, Wong T, Bready D, Tang K, Modrek AS, Placantonakis DG. Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics. *Front Oncol.* 2019;9:417.
Table and figure legends:

Table 1. Clinical and histological characteristics of tumors, and the distribution of IDH1 R132H immunohistochemical staining.

Figure 1. Infograph of our materials and results.

Figure 2. Staining pattern of the IDH1 R132H immunohistochemistry in the normal adrenal cortex and adrenocortical tumors. (A) Hematoxylin- and eosin-(HE) staining and (B) IDH R132H IHC of the normal adrenal cortex. (C) Score 0, (D) score 1, (E) score 2, and (F) score 3 of IDH1 R132H IHC. All images at 400x magnification.

Figure 3. Survival according to IDH1 R132H immunopositivity for tumours with Weiss score ≥3.
Table 1.

|                     | All tumors | Local tumors | Metastatic tumors | p-value |
|---------------------|------------|--------------|-------------------|---------|
| number of tumors    | 197        | 183          | 14                |         |
| Age (years)         | range      | 24–82        | 32–76             | 0.777   |
|                     | mean       | 54.2         | 55.5              |         |
|                     | median     | 55           | 54                |         |
| Gender*             | male       | 66           | 6                 | 0.560   |
|                     | female     | 129          | 8                 |         |
| Side                | right      | 101          | 8                 | 0.784   |
|                     | left       | 96           | 6                 |         |
| Size (cm)           | range      | 0.5–28.0     | 4–22              | <0.001  |
|                     | mean       | 3.4          | 2.8               |         |
|                     | median     | 2            | 2                 |         |
| Hormonal secretion | n          | 96           | 2                 | 0.010   |
| aldosterone         | %          | 49           | 14                |         |
| Cortisol            | n          | 74           | 7                 | 0.394   |
|                     | %          | 38           | 50                |         |
| androgens           | n          | 11           | 4                 | 0.004   |
|                     | %          | 6            | 29                |         |
| inactive            | n          | 29           | 5                 | 0.038   |
|                     | %          | 15           | 36                |         |
| Weiss score         | 0–2        | 164          | 0                 | <0.001  |
|                     | 3–9        | 33           | 14                |         |
| Helsinki score**   | ≤8.5       | 177          | 0                 | <0.001  |
|                     | ≥8.5       | 17           | 14                |         |
| IDH1 R132H score*** | 0          | 133          | 11                |         |
|                     | 1–3        | 62           | 3                 | 0.359   |
|                     |            | 1            | 1                 |         |
|                     |            | 3            | 0                 |         |
*One man and one woman had two separate tumors.

**The Helsinki score was determined for 194 tumors.

***IDH1 R132H immunohistochemistry was available for 195 tumors.
